Pre-Open Stock Movers 08/05: (RAX) (EGLT) (MRK) Higher; (HDP) (SWIR) (BMY) Lower (more...)

August 5, 2016 9:20 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Today's Pre-Open Stock Movers:

Hortonworks (NASDAQ: HDP) 32.9% LOWER; reported Q2 EPS of ($0.72), $0.02 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $43.6 million versus the consensus estimate of $45.26 million. GUIDANCE: Hortonworks sees Q3 2016 revenue of $45 million, versus the consensus of $49.3 million. Hortonworks sees FY2016 revenue of $177 million, versus the consensus of $191.4 million.

Rackspace (NYSE: RAX) 19.3% HIGHER; is in advanced talks to be sold to private equity, according to Dow Jones, citing sources. An agreement could be announced as soon as this week.

Sierra Wireless (NASDAQ: SWIR) 19.2% LOWER; Sierra Wireless (NASDAQ: SWIR) reported Q2 EPS of $0.20, $0.08 better than the analyst estimate of $0.12. Revenue for the quarter came in at $156.2 million versus the consensus estimate of $154.39 million. Lowers outlook.

Bristol-Myers Squibb Company (NYSE: BMY) 17.9% LOWER; announced that CheckMate -026, a trial investigating the use of Opdivo(nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at ≥ 5%. The company will complete a full evaluation of the CheckMate -026 data and work with investigators on the future presentation of the results.

FireEye (NASDAQ: FEYE) 16.4% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $175 million versus the consensus estimate of $181.67 million. GUIDANCE: FireEye sees Q3 2016 EPS of $0.30-$0.32, versus the consensus of ($0.24). FireEye sees Q3 2016 revenue of $180-186 million, versus the consensus of $208.23 million. FireEye sees FY2016 EPS of ($1.28)-($1.32), versus the consensus of ($1.24). FireEye sees FY2016 revenue of $716-728 million, versus the consensus of $793.74 million.

Egalet Corporation (Nasdaq: EGLT) 15.7% HIGHER; announced that the joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 18 to 1 to recommend approval of ARYMO ER (morphine sulfate). ARYMO ER was developed using Egalet's proprietary Guardian Technology for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Intellia Therapeutics (NASDAQ: NTLA) 15% HIGHER; Q2 results, upgraded at Leerink and Jefferies

Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) 14.9% LOWER; weak Q2 results

Pacific Bio (NASDAQ: PACB) 14.8% HIGHER; reported Q2 EPS of ($0.21), $0.01 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $20.19 million.

PDL BioPharma, Inc. (NASDAQ: PDLI) 14% LOWER; eliminates dividend

Universal Display (NASDAQ: OLED) 10.6% LOWER; reported Q2 EPS of $0.46, $0.04 worse than the analyst estimate of $0.50. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $68.68 million. Universal Display sees FY2016 revenue of $190-200 million, versus the consensus of $217.9 million.

Shares of Merck (NYSE: MRK) 10% HIGHER; Bristol-Myers Squibb's (NYSE: BMY) released disappointing results from CheckMate -026, phase 3 study of Opdivo for treatment of patients with NSCLC.

MasTec (NYSE: MTZ) 9.6% HIGHER; reported Q2 EPS of $0.36, $0.13 better than the analyst estimate of $0.23. Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $1.16 billion. GUIDANCE: MasTec sees FY2016 EPS of $1.57, versus the consensus of $1.41. MasTec sees FY2016 revenue of $5 billion, versus the consensus of $4.87 billion. MasTec sees Q3 2016 EPS of $0.64, versus the consensus of $0.61. MasTec sees Q3 2016 revenue of $1.5 billion, versus the consensus of $1.39 billion.

Osiris Therapeutics, Inc. (NASDAQ: OSIR) 8.5% HIGHER; announced today that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal, is now available online and will appear in an upcoming issue of the journal.

Aratana Therapeutics (NASDAQ: PETX) 7.9% HIGHER; reported Q2 EPS of $0.61, $0.37 better than the analyst estimate of $0.24. Revenue for the quarter came in at $38.05 million versus the consensus estimate of $7.61 million.

El Pollo Loco (NASDAQ: LOCO) 7.8% HIGHER; reported Q2 EPS of $0.19, $0.01 better than the analyst estimate of $0.18. Revenue for the quarter came in at $97.5 million versus the consensus estimate of $96.66 million. System-wide comparable restaurant sales grew 2.4%, including a 2.0% increase for company-operated restaurants, and a 2.7% increase for franchised restaurants. GUIDANCE: El Pollo Loco sees FY2016 EPS of $0.68-$0.72, versus the consensus of $0.69. System-wide comparable restaurant sales growth in the low single digits.

Weight Watchers (NYSE: WTW) 6.5% LOWER; reported Q2 EPS of $0.46, in-line with the analyst estimate of $0.46. Revenue for the quarter came in at $310 million versus the consensus estimate of $318.3 million. GUIDANCE: Weight Watchers sees FY2016 EPS of $0.90-$1.05, versus the consensus of $0.94.

The Priceline Group (NASDAQ: PCLN) 5.6% HIGHER; reported Q2 EPS of $13.93, $1.24 better than the analyst estimate of $12.69. Revenue for the quarter came in at $2.55 billion versus the consensus estimate of $2.58 billion. Sees Q3 EPS of $28.30-$29.30, versus the consensus of $28.99.

Ubiquiti Networks (NASDAQ: UBNT) 5.5% HIGHER; reported Q4 EPS of $0.69, $0.05 better than the analyst estimate of $0.64. Revenue for the quarter came in at $185.7 million versus the consensus estimate of $174.47 million. GUIDANCE: Ubiquiti Networks sees Q1 2017 EPS of $0.68-$0.74, versus the consensus of $0.61. Ubiquiti Networks sees Q1 2017 revenue of $180-190 million, versus the consensus of $171.31 million.

Lionsgate (NYSE: LGF) 5.3% HIGHER; reported Q1 EPS of $0.19, $0.36 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $553.6 million versus the consensus estimate of $494.34 million.

Zillow Group, Inc. (NASDAQ: ZG) 4.6% LOWER; reported Q2 EPS of ($0.71), $0.68 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $208.4 million versus the consensus estimate of $205.9 million. GUIDANCE: Zillow Group, Inc. sees Q3 2016 revenue of $217-222 million, versus the consensus of $217.13. Zillow Group, Inc. sees FY2016 revenue of $830-840 million, versus prior guidance of $825-835 million, versus the consensus of $831.5 million.

Organovo (NYSE: ONVO) 4% HIGHER; reported Q1 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $891 thousand versus the consensus estimate of $550 thousand. GUIDANCE: Organovo sees FY2016 revenue of $4-6 million, versus the consensus of $4.25 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Jefferies & Co, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, AdCom

Add Your Comment